Analysts Set Enfusion, Inc. (NYSE:ENFN) Price Target at $9.40

Shares of Enfusion, Inc. (NYSE:ENFN) have earned an average rating of “Reduce” from the five brokerages that are currently covering the company, MarketBeat Ratings reports. Three research analysts have rated the stock with a sell recommendation and two have issued a buy recommendation on the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $10.00.

Separately, Stifel Nicolaus increased their price target on shares of Enfusion from $11.00 to $13.00 and gave the stock a “buy” rating in a research note on Wednesday.

Enfusion Price Performance

ENFN opened at $10.63 on Wednesday. Enfusion has a one year low of $7.52 and a one year high of $11.38. The business has a 50 day simple moving average of $9.70 and a two-hundred day simple moving average of $9.00. The firm has a market capitalization of $1.37 billion, a price-to-earnings ratio of 265.82, a PEG ratio of 3.98 and a beta of 0.97.

Insider Activity at Enfusion

In other Enfusion news, COO Neal Pawar sold 21,801 shares of the company’s stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $10.03, for a total transaction of $218,664.03. Following the transaction, the chief operating officer now owns 1,143,544 shares in the company, valued at approximately $11,469,746.32. This represents a 1.87 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 36.44% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Enfusion

A number of institutional investors and hedge funds have recently modified their holdings of ENFN. RiverPark Advisors LLC bought a new stake in Enfusion during the second quarter valued at approximately $68,000. Arizona State Retirement System bought a new stake in shares of Enfusion during the 2nd quarter valued at $86,000. Harbor Capital Advisors Inc. grew its position in shares of Enfusion by 12.4% during the 3rd quarter. Harbor Capital Advisors Inc. now owns 11,887 shares of the company’s stock valued at $113,000 after acquiring an additional 1,315 shares during the period. Belvedere Trading LLC purchased a new stake in shares of Enfusion in the 3rd quarter worth $114,000. Finally, Paloma Partners Management Co bought a new position in Enfusion in the 3rd quarter worth $157,000. 81.05% of the stock is currently owned by hedge funds and other institutional investors.

About Enfusion

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.